Expansion Therapeutic has recently begun working on a campaign to raise series A funding for the purpose of increasing the efforts that it is making toward research into fighting a wide variety of genetic conditions in their portfolio of concern. Chief among these conditions is myotonic dystrophy type I which is a precursor disorder that is the leading cause of Adult Muscular Dystrophy. The currently accepted research indicated that the symptoms of DM1 begin to manifest once RNA levels reach toxic.
What has been found is that the production of some RNAs eventfully becomes toxic and trigger the effects of DM1. Unlike regular RNAs, molecules that are released from DNA strands and eventually convert into protein molecules which usually are harmless, these particular RNAs can have severe adverse reactions in the cells that contain them. The cells that are most susceptible this toxic RNA activity are the ones which are located in the heart, endocrine system, gastrointestinal tract, respiratory system, and central nervous system. As the cells at compromised the systems become defective and start to fail.
DM1 can affect entire families and can become worse with each subsequent generation. Expansion Therapeutics is committed to finding a solution to the problem of DM1. There is currently no known cure or treatment for DM1, but Expansion Therapeutics feels that they are on the right track. With the new resource pool of funding that was acquired by the campaign, this effort can now continue until a cure is found.
The funding campaign was led by Novartis Venture Fund, Sanofi Ventures, Kleiner Perkins, and 5AM ventures with Alexandria Venture Investments and RA Capital Management also being attached. A press release was issued by the managing partner of 5Am Ventures, Scott Rocklage on the funding campaign. Rocklage has been a leader in helping to fund advancements in medical research of all types with the goal being to help advance the understanding of illness and increase the benefits of medical science for mankind. Learn more: https://www.linkedin.com/in/scott-rocklage-66aa7a12a
Scott Rocklage has devoted his life, both in business and in the realm of science to the advancement of the understating of how science can be applied to the real world problems of everyday people. He started his company 5AM ventures to provide investment opportunities to those who share his dreams of a better world and to provide a secure source of funding to those research organizations and companies that are looking for cures to the worlds most incredulous diseases and conditions. He is a man who has spent the better part of his adulthood working to better the lives of others and continues to find new ways to make the world a better place every day in any way possible.